ALEC · Alector, Inc.

Track ALEC — free Ask ALVIS about ALEC

$1.65 +0.13 (+8.22%)

Market Cap

$168.76M

Shares

111.03M

Alector, Inc. Earnings Call Transcripts

Every quarterly earnings call for Alector, Inc. (ALEC) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts

▼29.6% $56.21M $1.38M '23 Q2 23-08-03 ▼38.7% $9.11M −$44.48M '23 Q3 23-11-07 ▲5.6% $15.23M −$41.43M '23 Q4 24-01-16 ▼3.9% $15.90M −$36.08M '24 Q1 24-05-08 ▼73.2% $15.08M −$38.68M '24 Q2 24-08-07 ▲256.1% $54.23M −$2.07M '24 Q4 25-02-26 LATEST ▼47.8% $7.87M −$30.52M '25 Q2 25-08-07

Alector, Inc. Q2 FY2025 Earnings Call

Confident tone FTD-GRN disease background and unmet need AL-101 early Alzheimer's Phase 2 Regulatory strategy and FDA engagement

Audio Transcript Slides 8-K10-Q

Alector, Inc. Q4 FY2024 Earnings Call

Positive tone Latozinemab Phase 3 INFRONT-3 in FTD granulin Alector Brain Carrier (ABC) platform AL101 in early Alzheimer's disease

Audio Transcript Slides 8-K10-K

Alector, Inc. Q2 FY2024 Earnings Call

Confident tone TREM2 mechanism / microglia biology differentiation INVOKE-2 Phase 2 AL002 data readout Latozinemab / INFRONT-3 pivotal Phase 3 in FTD-GRN

Audio Transcript Slides 8-K10-Q

Alector, Inc. Q1 FY2024 Earnings Call

Audio Transcript Slides 8-K10-Q

Alector, Inc. Q4 FY2023 Earnings Call

Positive tone AL002 / INVOKE-2 Phase 2 in Alzheimer's AL101 / PROGRESS-AD Phase 2 in early Alzheimer's Immuno-neurology / microglia mechanism

Audio Transcript Slides 8-K10-K

Alector, Inc. Q3 FY2023 Earnings Call

Audio Transcript Slides 8-K10-Q

Alector, Inc. Q2 FY2023 Earnings Call

Audio Transcript Slides 8-K10-Q

Showing 1–7 of 7 earnings calls

Key facts CIK 1653087 CUSIP 014442107 13F (30d) 20 filings 20 filers Visit website Investor relations